Migraine history and response to lasmiditan across racial and ethnic groups
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2057152
Abstract: Abstract Objective The robust enrollment in SPARTAN and SAMURAI provided the opportunity to present post-hoc descriptive details on migraine disease characteristics and treatment outcomes after treatment with lasmiditan, a selective serotonin (5-HT1F) receptor agonist, in… read more here.
Keywords: response lasmiditan; across racial; racial ethnic; ethnic groups ... See more keywords